|
|
|
|
|
|
|
Celldex Therapeutics (CLDX)
|
|
0.66 0.003 (0.5%)
|
05-22 09:51
|
|
Open:
|
0.66
|
Pre. Close:
|
0.6567
|
|
High:
|
0.667
|
Low:
|
0.66
|
|
Volume:
|
474,633
|
Market Cap:
|
95M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
0.695 - 0.701
|
0.701 - 0.705
|
|
Low:
|
0.636 - 0.645
|
0.645 - 0.65
|
|
Close:
|
0.65 - 0.664
|
0.664 - 0.672
|
|
|
|
Technical analysis (as of: 2018-05-21 4:27:46 PM)
|
|
Overall:
|
|
|
Stoxline posted a NEUTRAL today, same as yesterday. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next Buy or SELL signal.
|
|
Target:
|
Six months: 0.93  One year: 1.03
|
|
Support:
|
Support1: 0.65 Support2: 0.54
|
|
Resistance:
|
Resistance1:
0.79 Resistance2: 0.88
|
|
Pivot:
|
0.74
|
|
Moving Averages:
|
MA(5): 0.69 MA(20): 0.74
MA(100): 2.07 MA(250): 2.42
|
|
MACD:
|
MACD(12,26):
-0.21  Signal(12,26,9): -0.25
|
|
%K %D:
|
%K(14,3): 2.55 %D(3): 7.63
|
|
RSI:
|
RSI(14): 23.14
|
|
52-Week:
|
High: 3.26
Low: 0.65 Change(%): -78.7
|
|
Average Vol(K):
|
3-Month: 304245
10-Days 248122
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.CLDX has closed above bottom band by 5.2%. Bollinger Bands are 74% narrower than normal. The narrow width of the bands suggests low volatility as compared to CLDX's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-05-11T11:59:48-04:00
Celldex Trying To Regroup With Its Early-Stage Assets
2018-05-10T08:12:30-04:00
Celldex misses by $0.64, beats on revenue
2018-04-26T15:22:08-04:00
Biotech Analysis Central Pharma News: Takeda Raises Shire Bid, Daiichi Fails DMD Trial, Celldex Cuts 20% Of Workforce
2018-04-19T10:46:56-04:00
Celldex Nearly Back To Square One
2018-04-19T08:00:00-04:00
3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise
2018-04-18T13:54:41-04:00
OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner
2018-04-18T11:55:19-04:00
Celldex Tumbles On Phase 2 Trial Failure; Is There Any Value Left?
2018-04-17T02:29:11-04:00
Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
